(PDF) P3.01-55 SF2: A PCYT-2 Inhibitor Prototype Is Capable

P3.01-55 SF2: A PCYT-2 Inhibitor Prototype Is Capable of Inducing Citotoxicity in NSCLC

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.1615

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

P3.01-60 a Novel MET D1246H Mutation After Progression of EGFR-TKI/MET Inhibitor Combined Therapy in a NSCLC Patient With Acquired MET Amplification

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.01-20 Advanced NSCLC Treatment and Outcomes After Nivolumab

Journal of Thoracic Oncology

Respiratory Medicine

English

A Lysophosphatidic Acid Analogue Is Revealed as a Potent Inhibitor of Phosphatidylcholine Synthesis, Inducing Apoptosis

Biochemical Journal

Molecular Biology

English

Non Structural Protein of Avian Influenza a (H11N1) Virus Is a Weaker Suppressor of Immune Responses but Capable of Inducing Apoptosis in Host Cells

Virology Journal

Infectious Diseases

English

P3.01-97 Which Is Better Prognostic Factor, PS, Inflammatory Marker, or PD-L1 Expression in Treating NSCLC With Nivolmab; A Retrospective Analysis

Journal of Thoracic Oncology

Respiratory Medicine

English

Mixed Reviews for A2AR Inhibitor in NSCLC

Cancer Discovery

English

P3.01-51 Outcomes With Systemic Chemotherapy in Advanced NSCLC Patients With Performance Status 2 and Above and Without Driver Mutation

Journal of Thoracic Oncology

Respiratory Medicine

English

Antitumor Activity of Selective MEK1/2 Inhibitor AZD6244 in Combination With PI3K/mTOR Inhibitor BEZ235 in Gefitinib-Resistant NSCLC Xenograft Models

Journal of Experimental and Clinical Cancer Research

Cancer Research

English

P3.01-79 Intracerebral Efficacy of Immune Check-Point Inhibitors in NSCLC Patients With Brain Metastases

Journal of Thoracic Oncology

Respiratory Medicine

English